Search clinical trials for: HOE901-U300 (new formulation of insulin glargine)

Total 601 results

Sanofi

Terminated

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Type 1 Diabetes Mellitus

United States, Canada
Sanofi

Completed

Self Titration With Apidra to Reach Target Study (START)

Diabetes Mellitus, Type 2

Canada
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Clamp Study

Russian Federation
King Faisal Specialist Hospital & Research Center

Completed

Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) (GLUCOSE-in-PN)

Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition

Saudi Arabia
Eli Lilly and Company
Alkermes, Inc.

Completed

A Study for Patients With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan, Taiwan
Mylan Inc.
Mylan GmbH

Completed

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Type 1 Diabetes Mellitus

Czechia, United States, Canada, Estonia, Germany, Hungary, Latvia, Slovakia
Mylan Inc.
Mylan GmbH

Completed

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) (INSTRIDE 1)

Type 1 Diabetes

United States, Canada, Czechia, Estonia, Germany, Hungary, Latvia, Romania, Slovakia, South Africa, United Kingdom
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, South Africa, Canada
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, United States, Australia, Hungary, Poland, Romania, Spain
Sanofi

Completed

Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes (AFICIONADO)

Diabetes Mellitus, Type 2

Argentina
GWT-TUD GmbH

Completed

Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects (GLORY)

Type 2 Diabetes

Germany
Sanofi

Completed

Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients

Diabetes Mellitus, Type 1

Germany
University of Palermo

Completed

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Diabetes Mellitus

Italy
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Sanofi

Completed

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Diabetes Mellitus, Type 2

United States, Canada
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Buckinghamshire Healthcare NHS Trust
Novo Nordisk A/S

Unknown

Comparing Long-acting Insulins During Exercise in Type 1 Diabetes

Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment (EasyMix)

Diabetes Mellitus, Type 2 | Diabetes

Japan, China
Universidad Nacional de Asunción

Completed

Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay

Hyperglycemia | Diabetes

Paraguay
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
GlaxoSmithKline

Completed

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Diabetes Mellitus, Type 2

United States, Germany, Taiwan, South Africa, Korea, Republic of, Spain, Brazil, India, Peru, Philippines, United Kingdom, Hong Kong, France, Mexico
University Hospital Tuebingen

Terminated

Effects of Insulin Glargine and Lixisenatide on the Brain (Lixibrain01)

Diabetes Mellitus, Type 2

Germany
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
Inova Health Care Services

Terminated

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Diabetes Mellitus

United States
Mylan Inc.
Mylan GmbH

Completed

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2) (INSTRIDE 2)

Type 2 Diabetes

United States, Jordan, Korea, Republic of, Slovakia, South Africa, Taiwan
Eli Lilly and Company

Completed

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Diabetes Mellitus, Type 1 | Healthy Volunteers

United States
Sanofi

Completed

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
National Institute of Neurosciences and Hospital...

Completed

Insulin for Hyperglycemia in Stroke Trial

Hyperglycemia | Stroke, Acute

Bangladesh
Novo Nordisk A/S

Completed

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (SWITCH PRO)

Diabetes Mellitus, Type 2

United States, Slovakia, Canada, South Africa, Puerto Rico, Poland
Eli Lilly and Company

Completed

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

Type 1 Diabetes | Type 2 Diabetes

United States
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Health Care for Type 1 Diabetes in Developing World

Type 1 Diabetes

Rwanda
Sanofi

Completed

Insulin Glargine During and After the Period of Fasting in Ramadan

Diabetes Mellitus, Type 2
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Eli Lilly and Company

Completed

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Greece, India, Netherlands, Poland, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
Sanofi

Completed

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients (VARIABILITE)

Diabetes Mellitus, Type 1

France
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Pfizer

Completed

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

Diabetes Mellitus, Type 2

Germany, Netherlands, Sweden, Poland, Belgium, Finland, France, Norway, Spain, Switzerland
Sanofi

Completed

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Terminated

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (HMH)

Hyperglycemia

United States
Novo Nordisk A/S

Completed

The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins

Diabetes | Diabetes Mellitus, Type 1

Germany, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany

Search clinical trials for: HOE901-U300 (new formulation of insulin glargine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations